Infliximab in the Treatment of Plaque Type Psoriasis

Overview

Journal Clin Cosmet Investig Dermatol

Publisher Dove Medical Press

Specialty Dermatology

Date 2011 Mar 26

PMID 21436966

Citations 4

Authors

Rosita Saraceno

Andrea Saggini

Lucia Pietroleonardo

Sergio Chimenti

Affiliations

Soon will be listed here.

Abstract

Psoriasis is a chronic and immunomediated skin disease characterized by erythematous scaly plaques. Psoriasis affects approximately 1% to 3% of the Caucasian population. Tumor necrosis factor alpha (TNF-α) is a proinflammatory cytokine that plays a critical role in the pathogenesis of psoriasis. Infliximab is an anti-TNF-α drug widely used for the treatment of plaque type psoriasis and psoriatic arthritis. Controlled clinical trials demonstrated that infliximab is characterized by a high degree of clinical response in moderate to severe plaque psoriasis. Moreover infliximab showed rapid efficacy in nail psoriasis which represents a therapeutic challenge for dermatologists and a relevant source of distress for patients with plaque psoriasis. This anti-TNF-α has an encouraging safety profile, especially as long as physicians are watchful in prevention and early diagnosis of infections and infuse reactions. The efficacy, tolerability and safety profiles suggest infliximab as a suitable anti-psoriatic drug in the long-term treatment of a chronic disease such as plaque-type psoriasis.

Citing Articles

Psoriasis and inflammatory bowel disease: links and risks.

Vlachos C, Gaitanis G, Katsanos K, Christodoulou D, Tsianos E, Bassukas I Psoriasis (Auckl). 2018; 6:73-92.

PMID: 29387596 PMC: 5683131. DOI: 10.2147/PTT.S85194.

A dermatologist guide to immunogenicity.

Blattner C, Chaudhari S, Young 3rd J, Murase J Int J Womens Dermatol. 2017; 2(3):77-84.

PMID: 28492015 PMC: 5418886. DOI: 10.1016/j.ijwd.2016.05.001.

Effect of TNF-α inhibitors on transcriptional levels of pro-inflammatory interleukin-33 and Toll-like receptors-2 and -9 in psoriatic plaques.

Vageli D, Exarchou A, Zafiriou E, Doukas P, Doukas S, Roussaki-Schulze A Exp Ther Med. 2015; 10(4):1573-1577.

PMID: 26622528 PMC: 4577938. DOI: 10.3892/etm.2015.2688.

Dramatic response of nail psoriasis to infliximab.

Safa G, Darrieux L Case Rep Med. 2011; 2011:107928.

PMID: 21629846 PMC: 3099188. DOI: 10.1155/2011/107928.

References

Jacobstein D, Markowitz J, Kirschner B, Ferry G, Cohen S, Gold B . Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis. 2005; 11(5):442-6. DOI: 10.1097/01.mib.0000158166.88238.ea. View

Lecluse L, Piskin G, Mekkes J, Bos J, de Rie M . Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol. 2008; 159(3):527-36. DOI: 10.1111/j.1365-2133.2008.08728.x. View

Tan A, Benjamin M, Toumi H, Grainger A, Tanner S, Emery P . The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis--a high-resolution MRI and histological study. Rheumatology (Oxford). 2006; 46(2):253-6. DOI: 10.1093/rheumatology/kel214. View

Graves J, Nunley K, Heffernan M . Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol. 2006; 56(1):e55-79. DOI: 10.1016/j.jaad.2006.07.019. View

Cohen M, Reda D, Clegg D . Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. J Rheumatol. 1999; 26(8):1752-6. View

Kimball A, Jacobson C, Weiss S, Vreeland M, Wu Y . The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005; 6(6):383-92. DOI: 10.2165/00128071-200506060-00005. View

Felson D, Anderson J, Boers M, Bombardier C, Furst D, Goldsmith C . American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995; 38(6):727-35. DOI: 10.1002/art.1780380602. View

Reich K, Griffiths C, Barker J, Chimenti S, Dauden E, Giannetti A . Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus. Dermatology. 2008; 217(3):268-75. DOI: 10.1159/000149970. View

Desai S, Furst D . Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006; 20(4):757-90. DOI: 10.1016/j.berh.2006.06.002. View

10.

Griffiths C, Barker J . Pathogenesis and clinical features of psoriasis. Lancet. 2007; 370(9583):263-271. DOI: 10.1016/S0140-6736(07)61128-3. View

11.

McHugh N, Balachrishnan C, Jones S . Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003; 42(6):778-83. DOI: 10.1093/rheumatology/keg217. View

12.

Ghoreschi K, Weigert C, Rocken M . Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol. 2007; 25(6):574-80. DOI: 10.1016/j.clindermatol.2007.08.012. View

13.

PUCHNER T, Kugathasan S, Kelly K, Binion D . Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm Bowel Dis. 2001; 7(1):34-7. DOI: 10.1097/00054725-200102000-00005. View

14.

. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 2000; 49(RR-6):1-51. View

15.

Barnes P, Karin M . Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997; 336(15):1066-71. DOI: 10.1056/NEJM199704103361506. View

16.

Cheifetz A, Mayer L . Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med. 2005; 72(4):250-6. View

17.

Feldman S, Gottlieb A, Bala M, Wu Y, Eisenberg D, Guzzo C . Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol. 2008; 159(3):704-10. DOI: 10.1111/j.1365-2133.2008.08727.x. View

18.

Jones S, Armas J, Cohen M, Lovell C, Evison G, McHugh N . Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol. 1994; 33(9):834-9. DOI: 10.1093/rheumatology/33.9.834. View

19.

Kleyn C, Griffiths C . Infliximab for the treatment of psoriasis. Expert Opin Biol Ther. 2006; 6(8):797-805. DOI: 10.1517/14712598.6.8.797. View

20.

Antoni C, Krueger G, de Vlam K, Birbara C, Beutler A, Guzzo C . Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005; 64(8):1150-7. PMC: 1755609. DOI: 10.1136/ard.2004.032268. View